{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:51:23Z","timestamp":1789750283822,"version":"4.0.1"},"reference-count":96,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Introduction: Eravacycline is a new fluorocycline antibiotic with a broad spectrum of antimicrobial activity approved for the treatment of patients with complicated intra-abdominal infections. This systematic review aimed to evaluate the published data on the resistance of Gram-negative bacterial isolates to eravacycline. Methods: We identified relevant publications by systematically searching Embase, PubMed, Scopus, and Web of Science from their inception to 29 August 2025. Published antimicrobial resistance breakpoints of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the US Food and Drug Administration (FDA) were used. Results: Data on 59,922 Gram-negative bacterial clinical isolates were retrieved from 68 articles after the screening of 283 potentially relevant studies. The resistance of consecutive (non-selected) Escherichia coli ranged from 0.9% to 9.6%. The MIC50 values of eravacycline were \u22640.5 mg\/L for Acinetobacter baumannii isolates, including carbapenem-resistant A. baumannii, in the majority of studies. The proportions of resistance were higher among other lactose non-fermenting Gram-negative bacterial isolates, especially Pseudomonas aeruginosa, as well as among selected E. coli with advanced patterns of antimicrobial resistance. Conclusions: The evaluated data support the adequate antimicrobial activity of eravacycline against most Gram-negative bacterial clinical isolates. However, in vitro antimicrobial susceptibility testing and modern molecular diagnostic tests, including those that examine mechanisms of resistance, are helpful for the appropriate use of eravacycline in clinical practice.<\/jats:p>","DOI":"10.3390\/pathogens14121214","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T08:13:49Z","timestamp":1764576829000},"page":"1214","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Resistance of Gram-Negative Bacteria to Eravacycline: A Systematic Review of Data from In Vitro Studies"],"prefix":"10.3390","volume":"14","author":[{"given":"Matthew E.","family":"Falagas","sequence":"first","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 151 23 Marousi, Athens, Greece"},{"name":"School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus"},{"name":"Department of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura T.","family":"Romanos","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 151 23 Marousi, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios S.","family":"Kontogiannis","sequence":"additional","affiliation":[{"name":"Alfa Institute of Biomedical Sciences (AIBS), 151 23 Marousi, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-1641","authenticated-orcid":false,"given":"Charalampos","family":"Filippou","sequence":"additional","affiliation":[{"name":"School of Medicine, European University Cyprus, 2404 Nicosia, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9959-9978","authenticated-orcid":false,"given":"Drosos E.","family":"Karageorgopoulos","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 9DU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"ref_1","unstructured":"Shutter, M.C., and Akhondi, H. (2025). Tetracycline. StatPearls, StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Meng, R., Guan, X., Sun, L., Fei, Z., Li, Y., Luo, M., Ma, A., and Li, H. (2022). The Efficacy and Safety of Eravacycline Compared with Current Clinically Common Antibiotics in the Treatment of Adults with Complicated Intra-Abdominal Infections: A Bayesian Network Meta-Analysis. Front. Med., 9.","DOI":"10.3389\/fmed.2022.935343"},{"key":"ref_4","unstructured":"U.S. Food and Drug Administration (2025, September 23). XERAVA (Eravacycline) for Injection: Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf."},{"key":"ref_5","unstructured":"European Medicines Agency (2018). Xerava (Eravacycline): EPAR Product Information (English), European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xerava-epar-product-information_en.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S1201-9712(07)60001-0","article-title":"The Empiric Treatment of Nosocomial Intra-Abdominal Infections","volume":"11","author":"Dupont","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/jac\/dkae450","article-title":"In Vitro Activity and Genomic Characterization of KPC-Producing Klebsiella pneumoniae Clinical Blood Culture Isolates Resistant to Ceftazidime\/Avibactam, Meropenem\/Vaborbactam, Imipenem\/Relebactam: An Italian Nationwide Multicentre Observational Study (2022\u201323)","volume":"80","author":"Bianco","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s10096-025-05235-0","article-title":"Eravacycline: Evaluation of Susceptibility Testing Methods and Activity against Multidrug-Resistant Enterobacterales and Acinetobacter","volume":"44","author":"Bogaerts","year":"2025","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Liao, X., Liang, Q., Dai, X., Wu, S., Duan, C., Luo, Z., and Xie, X. (2024). In Vitro Activities of Eravacycline against Clinical Bacterial Isolates: A Multicenter Study in Guangdong, China. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1504013"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e04873-22","DOI":"10.1128\/spectrum.04873-22","article-title":"In Vitro Activities of Aztreonam-Avibactam, Eravacycline, Cefoselis, and Other Comparators against Clinical Enterobacterales Isolates: A Multicenter Study in China, 2019","volume":"11","author":"Chen","year":"2023","journal-title":"Microbiol. Spectr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.diagmicrobio.2017.12.013","article-title":"In Vitro Activity of Eravacycline against 2213 Gram-Negative and 2424 Gram-Positive Bacterial Pathogens Isolated in Canadian Hospital Laboratories: CANWARD Surveillance Study 2014\u20132015","volume":"91","author":"Zhanel","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/AAC.04809-14","article-title":"Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City","volume":"59","author":"Abdallah","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, Randomized, Double-Blind Study of the Efficacy and Safety of Two Dose Regimens of Eravacycline versus Ertapenem for Adult Community-Acquired Complicated Intra-Abdominal Infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e01065-24","DOI":"10.1128\/aac.01065-24","article-title":"Population Pharmacokinetics and Pulmonary Modeling of Eravacycline and the Determination of Microbiological Breakpoint and Cutoff of PK\/PD","volume":"69","author":"Ji","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.cmi.2024.10.012","article-title":"Potent in Vitro Activity of Sulbactam-Durlobactam against NDM-Producing Escherichia Coli Including Cefiderocol and Aztreonam-Avibactam-Resistant Isolates","volume":"31","author":"Nordmann","year":"2025","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmii.2025.01.006","article-title":"Antimicrobial Resistance among Imipenem-Non-Susceptible Escherichia Coli and Klebsiella pneumoniae Isolates, with an Emphasis on Novel \u03b2-Lactam\/\u03b2-Lactamase Inhibitor Combinations and Tetracycline Derivatives: The Taiwan Surveillance of Antimicrobial Resistance Program, 2020\u20132022","volume":"58","author":"Lee","year":"2025","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Garc\u00eda, P., Guijarro-S\u00e1nchez, P., Lasarte-Monterrubio, C., Muras, A., Alonso-Garc\u00eda, I., Outeda-Garc\u00eda, M., Maceiras, R., Fern\u00e1ndez-L\u00f3pez, M.D.C., Rodr\u00edguez-Coello, A., and Garc\u00eda-Pose, A. (2024). Activity and Resistance Mechanisms of the Third Generation Tetracyclines Tigecycline, Eravacycline and Omadacycline against Nationwide Spanish Collections of Carbapenemase-Producing Enterobacterales and Acinetobacter baumannii. Biomed. Pharmacother., 181.","DOI":"10.1016\/j.biopha.2024.117666"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Han, Y., Xiong, Y., Wang, M., Wang, J., Song, T., Yu, J., Hu, J., Zhao, Z., Li, M., and Li, Y. (2024). Small RNA-Regulated Expression of Efflux Pump Affects Tigecycline Resistance and Heteroresistance in Clinical Isolates of Klebsiella pneumoniae. Microbiol. Res., 287.","DOI":"10.1016\/j.micres.2024.127825"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jmii.2022.09.009","article-title":"In Vitro Susceptibility of Common Enterobacterales to Eravacycline in Taiwan","volume":"56","author":"Huang","year":"2023","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Markovska, R., Stankova, P., Stoeva, T., Keuleyan, E., Mihova, K., and Boyanova, L. (2024). In Vitro Antimicrobial Activity of Five Newly Approved Antibiotics against Carbapenemase-Producing Enterobacteria\u2014A Pilot Study in Bulgaria. Antibiotics, 13.","DOI":"10.3390\/antibiotics13010081"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Markovska, R., Stankova, P., Popivanov, G., Gergova, I., Mihova, K., Mutafchiyski, V., and Boyanova, L. (2024). Emergence of blaNDM-5 and blaOXA-232 Positive Colistin- and Carbapenem-Resistant Klebsiella pneumoniae in a Bulgarian Hospital. Antibiotics, 13.","DOI":"10.3390\/antibiotics13070677"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"S\u0142abisz, N., Le\u015bnik, P., Janc, J., Fidut, M., Bartoszewicz, M., Dudek-Wicher, R., and Nawrot, U. (2024). Evaluation of the in Vitro Susceptibility of Clinical Isolates of NDM-Producing Klebsiella pneumoniae to New Antibiotics Included in a Treatment Regimen for Infections. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1331628"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107341","DOI":"10.1016\/j.ijantimicag.2024.107341","article-title":"In-Vitro Activities of Essential Antimicrobial Agents Including Aztreonam\/Avibactam, Eravacycline, Colistin and Other Comparators against Carbapenem-Resistant Bacteria with Different Carbapenemase Genes: A Multi-Centre Study in China, 2021","volume":"64","author":"Wu","year":"2024","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e00107-24","DOI":"10.1128\/spectrum.00107-24","article-title":"Effect of Ceftazidime-Avibactam Combined with Different Antimicrobials against Carbapenem-Resistant Klebsiella pneumoniae","volume":"12","author":"Wu","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liu, D., Liu, Y., Li, Q., Liu, H., Zhou, P., Liu, Y., Chen, L., Yin, W., and Lu, Y. (2024). Detection and Characterization of Eravacycline Heteroresistance in Clinical Bacterial Isolates. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1332458"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bonnin, R.A., Bernabeu, S., Emeraud, C., Naas, T., Girlich, D., Jousset, A.B., and Dortet, L. (2023). In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales. Antibiotics, 12.","DOI":"10.3390\/antibiotics12010102"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","article-title":"In Vitro Activity of Eravacycline and Comparators against Gram-Negative and Gram-Positive Bacterial Isolates Collected from Patients Globally between 2017 and 2020","volume":"33","author":"Hawser","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jiph.2024.03.027","article-title":"Evaluation of the Synergistic Effect of Eravacycline and Tigecycline against Carbapenemase-Producing Carbapenem-Resistant Klebsiella pneumoniae","volume":"17","author":"Huang","year":"2024","journal-title":"J. Infect. Public Health"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jgar.2023.02.011","article-title":"Multidrug-Resistant Enterobacterales Responsible for Septicaemia in a Neonatal Intensive Care Unit in Morocco","volume":"33","author":"Girlich","year":"2023","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.2147\/IDR.S396910","article-title":"Antibacterial Activity of Eravacycline Against Carbapenem-Resistant Gram-Negative Isolates in China: An in Vitro Study","volume":"16","author":"Zou","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.3855\/jidc.17349","article-title":"Susceptibility of Carbapenem-Resistant Enterobacterales Isolates to New Antibiotics from a Tertiary Care Hospital, Egypt: A Matter of Hope","volume":"16","author":"Badran","year":"2022","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1120009X.2021.1965335","article-title":"In Vitro Susceptibility of Carbapenem-Resistant Enterobacterales to Eravacycline\u2014The First Report from Croatia","volume":"34","year":"2022","journal-title":"J. Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Kore\u0148, J., Andrez\u00e1l, M., Drahovsk\u00e1, H., Huben\u00e1kov\u00e1, Z., Lipt\u00e1kov\u00e1, A., and Maliar, T. (2022). Next-Generation Sequencing of Carbapenem-Resistant Klebsiella pneumoniae Strains Isolated from Patients Hospitalized in the University Hospital Facilities. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111538"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","article-title":"Synergism of Eravacycline Combined with Other Antimicrobial Agents against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"30","author":"Li","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s15010-021-01735-1","article-title":"Epidemiology and in Vitro Activity of Ceftazidime\u2013Avibactam, Meropenem\u2013Vaborbactam, Imipenem\u2013Relebactam, Eravacycline, Plazomicin, and Comparators against Greek Carbapenemase-Producing Klebsiella pneumoniae Isolates","volume":"50","author":"Maraki","year":"2022","journal-title":"Infection"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Johnston, B.D., Thuras, P., Porter, S.B., Clabots, C., and Johnsona, J.R. (2021). Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Extended-Spectrum Cephalosporin-Resistant Escherichia Coli Clinical Isolates (2012\u20132017) in Relation to Phylogenetic Background, Sequence Type 131 Subclones, blaCTX-M Genotype, and Coresistance. Diagn. Microbiol. Infect. Dis., 100.","DOI":"10.1016\/j.diagmicrobio.2021.115314"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1093\/jac\/dkab141","article-title":"In Vitro Activity of Imipenem\/Relebactam, Meropenem\/Vaborbactam, Ceftazidime\/Avibactam, Cefepime\/Zidebactam and Other Novel Antibiotics against Imipenem-Non-Susceptible Gram-Negative Bacilli from Taiwan","volume":"76","author":"Kuo","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"106377","DOI":"10.1016\/j.ijantimicag.2021.106377","article-title":"In-Vitro Activity of Cefiderocol, Cefepime\/Zidebactam, Cefepime\/Enmetazobactam, Omadacycline, Eravacycline and Other Comparative Agents against Carbapenem-Nonsusceptible Enterobacterales: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017\u20132020","volume":"58","author":"Lee","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e00203-21","DOI":"10.1128\/AAC.00203-21","article-title":"Novel Specific Metallo-b-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM\u2014Positive Enterobacterales","volume":"65","author":"Zalacain","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"106178","DOI":"10.1016\/j.ijantimicag.2020.106178","article-title":"In Vitro Activity of Eravacycline Compared with Tigecycline against Carbapenem-Resistant Enterobacteriaceae","volume":"56","author":"Clark","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e00797-20","DOI":"10.1128\/AAC.00797-20","article-title":"Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia Coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e01699-19","DOI":"10.1128\/AAC.01699-19","article-title":"In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017","volume":"64","author":"Morrissey","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Zhao, C., Wang, X., Zhang, Y., Wang, R., Wang, Q., Li, H., and Wang, H. (2019). In Vitro Activities of Eravacycline against 336 Isolates Collected from 2012 to 2016 from 11 Teaching Hospitals in China. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4093-1"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1128\/AAC.02403-15","article-title":"Activity of Eravacycline against Escherichia Coli Clinical Isolates Collected from U.S. Veterans in 2011 in Relation to Coresistance Phenotype and Sequence Type 131 Genotype","volume":"60","author":"Johnson","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/ja.2016.73","article-title":"In Vitro Susceptibility of \u03b2-Lactamase-Producing Carbapenem-Resistant Enterobacteriaceae (CRE) to Eravacycline","volume":"69","author":"Zhang","year":"2016","journal-title":"J. Antibiot."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ataman, M., and \u00c7elik, B.\u00d6. (2025). Investigation of the in Vitro Antimicrobial Activity of Eravacycline Alone and in Combination with Various Antibiotics against MDR Acinetobacter Baumanni Strains. BMC Microbiol., 25.","DOI":"10.1186\/s12866-025-03914-8"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e00379-25","DOI":"10.1128\/aac.00379-25","article-title":"Activity of Ampicillin-Sulbactam, Sulbactam-Durlobactam, and Comparators against Acinetobacter baumannii-calcoaceticus Complex Strains Isolated from Respiratory and Bloodstream Sources: Results from ACNBio Study","volume":"69","author":"Buyukyanbolu","year":"2025","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/mdr.2024.0220","article-title":"Species Distribution and Antimicrobial Susceptibility of Diverse Strains Within Burkholderia cepacia Complex","volume":"31","author":"Li","year":"2025","journal-title":"Microb. Drug Resist."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"107560","DOI":"10.1016\/j.micpath.2025.107560","article-title":"An Assessment of Cefiderocol\u2019s Synergistic Effects with Eravacycline, Colistin, Meropenem, Levofloxacin, Ceftazidime\/Avibactam, and Tobramycin against Carbapenem-Resistant and -Susceptible Pseudomonas aeruginosa","volume":"204","author":"Yilmaz","year":"2025","journal-title":"Microb. Pathog."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Gautam, H., Raza, S., Biswas, J., Mohapatra, S., Sood, S., Dhawan, B., Kapil, A., and Das, B.K. (2024). Antimicrobial Efficacy of Eravacycline against Emerging Extensively Drug-Resistant (XDR) Acinetobacter baumannii Isolates. Indian J. Med. Microbiol., 48.","DOI":"10.1016\/j.ijmmb.2024.100565"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jgar.2024.03.014","article-title":"Antimicrobial Activity of Eravacycline and Other Comparative Agents on Aerobic and Anaerobic Bacterial Pathogens in Taiwan: A Clinical Microbiological Study","volume":"37","author":"Tsai","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jgar.2024.01.023","article-title":"In Vitro Activity of Cefiderocol against Gram-Negative Pathogens Isolated from People with Cystic Fibrosis and Bronchiectasis","volume":"36","author":"Tunney","year":"2024","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e01120-23","DOI":"10.1128\/aac.01120-23","article-title":"Meropenem-ANT3310, a Unique \u03b2-Lactam-\u03b2-Lactamase Inhibitor Combination with Expanded Antibacterial Spectrum against Gram-Negative Pathogens Including Carbapenem-Resistant Acinetobacter baumannii","volume":"68","author":"Zalacain","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10096-023-04616-7","article-title":"In Vitro Activities of Omadacycline, Eravacycline, Cefiderocol, Apramycin, and Comparator Antibiotics against Acinetobacter baumannii Causing Bloodstream Infections in Greece, 2020\u20132021: A Multicenter Study","volume":"42","author":"Galani","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Deolankar, M.S., Carr, R.A., Fliorent, R., Roh, S., Fraimow, H., and Carabetta, V.J. (2022). Evaluating the Efficacy of Eravacycline and Omadacycline against Extensively Drug-Resistant Acinetobacter baumannii Patient Isolates. Antibiotics, 11.","DOI":"10.3390\/antibiotics11101298"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lee, Y.-T., Chen, H.-Y., Yang, Y.-S., Chou, Y.-C., Chang, T.-Y., Hsu, W.-J., Lin, I.-C., and Sun, J.-R. (2020). AdeABC Efflux Pump Controlled by AdeRS Two Component System Conferring Resistance to Tigecycline, Omadacycline and Eravacycline in Clinical Carbapenem Resistant Acinetobacter nosocomialis. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.584789"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/jac\/dkae426","article-title":"Comparative Evaluation of Eravacycline Susceptibility Testing Methods in 587 Clinical Carbapenem-Resistant Acinetobacter baumannii Isolates: Broth Microdilution, MIC Test Strip and Disc Diffusion","volume":"80","author":"Liu","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41429-024-00801-8","article-title":"Activity of Cefiderocol in Combination with Tetracycline Analogues against Carbapenem-Resistant Acinetobacter baumannii","volume":"78","author":"Yin","year":"2025","journal-title":"J. Antibiot."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chen, X., Li, Y., Lin, Y., Guo, Y., He, G., Wang, X., Wang, M., Xu, J., Song, M., and Tan, X. (2024). Comparison of Antimicrobial Activities and Resistance Mechanisms of Eravacycline and Tigecycline against Clinical Acinetobacter baumannii Isolates in China. Front. Microbiol., 15.","DOI":"10.3389\/fmicb.2024.1417237"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Halim, J., Carr, R.A., Fliorent, R., Jonnalagadda, K., Kurbonnazarova, M., Kaur, M., Millstein, I., and Carabetta, V.J. (2024). Combinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Acinetobacter baumannii Patient Isolates. Microorganisms, 12.","DOI":"10.3390\/microorganisms12071353"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, Y., Chen, X., Guo, Y., Lin, S., Wang, M., Xu, J., Wang, X., He, G., Tan, X., and Zhuo, C. (2024). Emergence of Eravacycline Heteroresistance in Carbapenem-Resistant Acinetobacter baumannii Isolates in China. Front. Cell. Infect. Microbiol., 14.","DOI":"10.3389\/fcimb.2024.1356353"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e00086-24","DOI":"10.1128\/spectrum.00086-24","article-title":"A Panel of Genotypically and Phenotypically Diverse Clinical Acinetobacter baumannii Strains for Novel Antibiotic Development","volume":"12","author":"Sun","year":"2024","journal-title":"Microbiol. Spectr."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Camargo, C.H., Yamada, A.Y., de Souza, A.R., Cunha, M.P.V., Ferraro, P.S.P., Sacchi, C.T., Dos Santos, M.B., Campos, K.R., Tiba-Casas, M.R., and Freire, M.P. (2023). Genomic Analysis and Antimicrobial Activity of \u03b2-Lactam\/\u03b2-Lactamase Inhibitors and Other Agents against KPC-Producing Klebsiella pneumoniae Clinical Isolates from Brazilian Hospitals. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-41903-x"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s10096-023-04583-z","article-title":"Enhanced Bacterial Killing with a Combination of Sulbactam\/Minocycline against Dual Carbapenemase-Producing Acinetobacter baumannii","volume":"42","author":"Chandran","year":"2023","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.pathol.2022.09.007","article-title":"Limited in Vitro Susceptibility of Drug-Resistant Non-Fermenting Gram-Negative Organisms against Newer Generation Antibiotics","volume":"55","author":"Chew","year":"2023","journal-title":"Pathology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/jcb.30424","article-title":"Determination of Potential Combination of Non-\u03b2-lactam, \u0392-lactam, and \u0392-lactamase Inhibitors\/\u0392-lactam Enhancer against Class D Oxacillinases Producing Acinetobacter baumannii: Evidence from In-vitro, Molecular Docking and Dynamics Simulation","volume":"124","author":"Gopikrishnan","year":"2023","journal-title":"J. Cell. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6005","DOI":"10.2147\/IDR.S425061","article-title":"In Vitro Antimicrobial Activity and Dose Optimization of Eravacycline and Other Tetracycline Derivatives Against Levofloxacin-Non-Susceptible and\/or Trimethoprim-Sulfamethoxazole-Resistant Stenotrophomonas Maltophilia","volume":"16","author":"Wu","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jmii.2021.08.012","article-title":"In Vitro Activity of Cefiderocol, Cefepime\/Enmetazobactam, Cefepime\/Zidebactam, Eravacycline, Omadacycline, and Other Comparative Agents against Carbapenem-Non-Susceptible Pseudomonas aeruginosa and Acinetobacter baumannii Isolates Associated from Bloodstream Infection in Taiwan between 2018\u20132020","volume":"55","author":"Liu","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/1120009X.2021.2005755","article-title":"In Vitro and in Vivo Comparison of Eravacycline- and Tigecycline-Based Combination Therapies for Tigecycline-Resistant Acinetobacter baumannii","volume":"34","author":"Yin","year":"2022","journal-title":"J. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e01603-19","DOI":"10.1128\/JCM.01603-19","article-title":"Activity of Potential Alternative Treatment Agents for Stenotrophomonas Maltophilia Isolates Nonsusceptible to Levofloxacin and\/or Trimethoprim-Sulfamethoxazole","volume":"58","author":"Biagi","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"105829","DOI":"10.1016\/j.ijantimicag.2019.10.010","article-title":"In Vitro Activity of the Novel Fluorocycline TP-6076 against Carbapenem-Resistant Acinetobacter baumannii","volume":"55","author":"Seifert","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ijantimicag.2017.06.022","article-title":"In-Vitro Activity of the Novel Fluorocycline Eravacycline against Carbapenem Non-Susceptible Acinetobacter baumannii","volume":"51","author":"Seifert","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/jac\/dkae220","article-title":"Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus","volume":"79","author":"Jing","year":"2024","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Camargo, C.H., Yamada, A.Y., de Souza, A.R., Lima, M.D.J.D.C., Cunha, M.P.V., Ferraro, P.S.P., Sacchi, C.T., dos Santos, M.B.N., Campos, K.R., and Tiba-Casas, M.R. (2023). Genomics and Antimicrobial Susceptibility of Clinical Pseudomonas aeruginosa Isolates from Hospitals in Brazil. Pathogens, 12.","DOI":"10.3390\/pathogens12070918"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1128\/JCM.00001-14","article-title":"Major variation in MICs of tigecycline in Gram-negative bacilli as a function of testing method","volume":"52","author":"Marchaim","year":"2014","journal-title":"J Clin Microbiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkn165","article-title":"Tigecycline for the Treatment of Multidrug-Resistant (Including Carbapenem-Resistant) Acinetobacter Infections: A Review of the Scientific Evidence","volume":"62","author":"Karageorgopoulos","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kakoullis, L., Papachristodoulou, E., Chra, P., and Panos, G. (2021). Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions. Antibiotics, 10.","DOI":"10.3390\/antibiotics10040415"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(08)70279-2","article-title":"Current Control and Treatment of Multidrug-Resistant Acinetobacter baumannii Infections","volume":"8","author":"Karageorgopoulos","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijantimicag.2014.12.031","article-title":"Tetracyclines for Multidrug-Resistant Acinetobacter baumannii Infections","volume":"45","author":"Falagas","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.ijantimicag.2018.03.009","article-title":"Activity of TP-6076 against Carbapenem-Resistant Acinetobacter baumannii Isolates Collected from Inpatients in Greek Hospitals","volume":"52","author":"Falagas","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_84","unstructured":"(2025, September 23). A Phase 3, Randomized, Multicenter, Double-Blind, Double-Dummy, Parallel-Group, Comparative Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Ertapenem in the Treatment of Complicated Intra-Abdominal Infections (cIAI) in Hospitalized Adults. Available online: https:\/\/www.chictr.org.cn\/showproj.html?proj=37134."},{"key":"ref_85","unstructured":"(2025, September 23). A Phase II\/III, Randomized, Two-Stage Clinical Study to Assess the Efficacy, Safety and Tolerability of Eravacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adult Subjects. Available online: https:\/\/www.chictr.org.cn\/showproj.html?proj=149425."},{"key":"ref_86","unstructured":"(2025, September 23). Efficacy and Safety of Eravacycline for Complicated Intra-Abdominal Infections in the ICU: A Multicenter, Single-Blind, Parallel Randomized Controlled Trial Study. Available online: https:\/\/www.chictr.org.cn\/showproj.html?proj=208164."},{"key":"ref_87","unstructured":"Tetraphase Pharmaceuticals, Inc (2025, September 23). A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Intra-Abdominal Infections, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01844856."},{"key":"ref_88","unstructured":"Tetraphase Pharmaceuticals, Inc (2025, September 23). A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Meropenem in Complicated Intra-Abdominal Infections, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT02784704."},{"key":"ref_89","unstructured":"Tetraphase Pharmaceuticals, Inc (2025, September 23). A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated Urinary Tract Infections, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT01978938."},{"key":"ref_90","unstructured":"Tetraphase Pharmaceuticals, Inc (2025, September 24). A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared with Ertapenem in Complicated Urinary Tract Infections, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT030325."},{"key":"ref_91","unstructured":"Cumpston, A. (2025, September 24). Prospective Evaluation of XeravaTM (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT05537896."},{"key":"ref_92","unstructured":"Tetraphase Pharmaceuticals, Inc (2025, September 24). Multicenter, Open-Label Trial to Evaluate the Safety and Tolerability of Intravenous Eravacycline in Pediatric Patients from 8 Years to Less than 18 Years of Age with Complicated Intra-Abdominal Infections (cIAI), Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT06794541."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40265-019-01067-3","article-title":"Eravacycline: A Review in Complicated Intra-Abdominal Infections","volume":"79","author":"Scott","year":"2019","journal-title":"Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Haeili, M., Aghajanzadeh, M., Moghaddasi, K., Omrani, M., Ghodousi, A., and Cirillo, D.M. (2025). Emergence of Transferable Tigecycline and Eravacycline Resistance Gene tet(X4) in Escherichia Coli Isolates from Iran. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-98206-6"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3343\/alm.2021.41.3.293","article-title":"In Vitro Activity of the Novel Tetracyclines, Tigecycline, Eravacycline, and Omadacycline, Against Moraxella catarrhalis","volume":"41","author":"Sun","year":"2021","journal-title":"Ann. Lab. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e01390-22","DOI":"10.1128\/spectrum.01390-22","article-title":"Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies","volume":"10","author":"Xu","year":"2022","journal-title":"Microbiol. Spectr."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/12\/1214\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T05:27:12Z","timestamp":1764653232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/14\/12\/1214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":96,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["pathogens14121214"],"URL":"https:\/\/doi.org\/10.3390\/pathogens14121214","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]}}}